Clinical Trial Update: Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension

View source ↗

Summary

Pfizer-sponsored clinical trial evaluating spironolactone plus hydroflumethiazide for hypertension in Filipino patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Hydroflumethiazide (Hydroflumethiazide)
• Spironolactone (spironolactone)

Snippet

Sponsor: Pfizer | Conditions: Hypertension | Status: WITHDRAWN